Larotrectinib

Major

Larotrectinib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Larotrectinib Abametapir Explained Increased exposure of CYP3A4 substrate Details Larotrectinib Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Larotrectinib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine-related toxicity Details Larotrectinib Simvastatin Flolipid Explained Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Acalabrutinib Calquence Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Avapritinib Ayvakit Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Avanafil Stendra Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Bedaquiline Sirturo Increased bedaquiline exposure Details Larotrectinib Bosutinib Bosulif Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Budesonide Entocort Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Budesonide Nasal Spray Rhinocort Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Budesonide Oral Inhalation Pulmicort Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Cobimetinib Cotellic Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Cyclosporine Injection Atopica Increased larotrectinib exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Cyclosporine Ophthalmic Cequa Increased larotrectinib exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Dasatinib Phyrago Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Larotrectinib Entrectinib Rozlytrek Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Everolimus Afinitor Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Felodipine Plendil® Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Fentanyl Transdermal Patch Duragesic® Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Larotrectinib Finerenone Kerendia Increased sensitive CYP3A4 substrate (finerenone) exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Ibrexafungerp Brexafemme Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Ibrutinib Imbruvica Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Ivabradine Corlanor Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Ketoconazole Topical Extina® Foam Increased larotrectinib exposure Details Larotrectinib Letermovir Injection Prevymis Increased larotrectinib exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Larotrectinib Lovastatin Altocor® Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Lurasidone Latuda Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Maraviroc Selzentry Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Methylergonovine Methergine Increased methylergonovine exposure Details Larotrectinib Midazolam Nasal Spray Nayzilam Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Midazolam Injection Nayzilam Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Nafcillin Injection Unipen® Injection Reduced larotrectinib exposure Details Larotrectinib Naloxegol Movantik Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Larotrectinib Nifedipine Adalat® Increased NIFEdipine exposure Details

Moderate

Larotrectinib Dofetilide Tikosyn Increased dofetilide exposure Details Larotrectinib Hydrocortisone Ala-Cort Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details